Clovis Oncology (CLVS) Announces Pricing Of $250 Million Of Convertible Senior Notes
9/4/2014 12:36:52 PM
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the pricing of $250 million aggregate principal amount of its 2.50% convertible senior notes due 2021 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Clovis Oncology has also granted the initial purchasers a 30-day option to purchase up to $37.5 million aggregate principal amount of additional notes on the same terms and conditions.
Help employers find you! Check out all the jobs and post your resume.
comments powered by